Literature DB >> 26926642

Aminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant Klebsiella pneumoniae.

Ryan K Shields1, Cornelius J Clancy2, Ellen G Press3, M Hong Nguyen1.   

Abstract

Aminoglycoside treatment of carbapenem-resistant (CR) Klebsiella pneumoniae bacteremia was associated with a 70% rate (23/33) of 30-day survival. Successful treatment was associated with sources of bacteremia amenable to reliable aminoglycoside pharmacokinetics (P = 0.037), acute physiology and chronic health evaluation II (APACHE II) scores of <20 (P = 0.16), and nonfatal underlying diseases (P = 0.015). Success rates were 78% and 100% if ≥2 and all 3 factors were present, respectively. Clinicians may consider the use of aminoglycosides against CR K. pneumoniae bacteremia if strains are susceptible and the sources of infection are amenable to reliable pharmacokinetics.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26926642      PMCID： PMC4862490          DOI： 10.1128/AAC.02638-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  30 in total

1.  Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates.

Authors:  D M Livermore; S Mushtaq; M Warner; J-C Zhang; S Maharjan; M Doumith; N Woodford
Journal:  J Antimicrob Chemother       Date:  2010-11-14       Impact factor: 5.790

2.  Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study.

Authors:  D R Giacobbe; V Del Bono; E M Trecarichi; F G De Rosa; M Giannella; M Bassetti; A Bartoloni; A R Losito; S Corcione; M Bartoletti; E Mantengoli; C Saffioti; N Pagani; S Tedeschi; T Spanu; G M Rossolini; A Marchese; S Ambretti; R Cauda; P Viale; C Viscoli; M Tumbarello
Journal:  Clin Microbiol Infect       Date:  2015-08-14       Impact factor: 8.067

3.  Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study.

Authors:  Mario Tumbarello; Enrico Maria Trecarichi; Francesco Giuseppe De Rosa; Maddalena Giannella; Daniele Roberto Giacobbe; Matteo Bassetti; Angela Raffaella Losito; Michele Bartoletti; Valerio Del Bono; Silvia Corcione; Giuseppe Maiuro; Sara Tedeschi; Luigi Celani; Chiara Simona Cardellino; Teresa Spanu; Anna Marchese; Simone Ambretti; Roberto Cauda; Claudio Viscoli; Pierluigi Viale
Journal:  J Antimicrob Chemother       Date:  2015-04-21       Impact factor: 5.790

4.  Treatment of KPC-producing Enterobacteriaceae: suboptimal efficacy of polymyxins.

Authors:  M S de Oliveira; D B de Assis; M P Freire; G V Boas do Prado; A S Machado; E Abdala; L C Pierrotti; C Mangini; L Campos; H H Caiaffa Filho; A S Levin
Journal:  Clin Microbiol Infect       Date:  2014-10-13       Impact factor: 8.067

5.  Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients.

Authors:  C J Clancy; L Chen; R K Shields; Y Zhao; S Cheng; K D Chavda; B Hao; J H Hong; Y Doi; E J Kwak; F P Silveira; R Abdel-Massih; T Bogdanovich; A Humar; D S Perlin; B N Kreiswirth; M Hong Nguyen
Journal:  Am J Transplant       Date:  2013-09-06       Impact factor: 8.086

6.  Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae.

Authors:  Marcelino Gonzalez-Padilla; Julián Torre-Cisneros; Francisco Rivera-Espinar; Antonio Pontes-Moreno; Lorena López-Cerero; Alvaro Pascual; Clara Natera; Marina Rodríguez; Inmaculada Salcedo; Fernando Rodríguez-López; Antonio Rivero; Jesús Rodríguez-Baño
Journal:  J Antimicrob Chemother       Date:  2014-10-25       Impact factor: 5.790

7.  Pharmacology of gentamicin in man.

Authors:  L J Riff; G G Jackson
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

8.  Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents.

Authors:  Reem Almaghrabi; Cornelius J Clancy; Yohei Doi; Binghua Hao; Liang Chen; Ryan K Shields; Ellen G Press; Nicole M Iovine; Bethany M Townsend; Marilyn M Wagener; Barry Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

9.  Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance.

Authors:  J Blaser; B B Stone; M C Groner; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

10.  Aminoglycosides for intra-abdominal infection: equal to the challenge?

Authors:  Jeffrey A Bailey; Katherine S Virgo; Joseph T DiPiro; Avery B Nathens; Robert G Sawyer; John E Mazuski
Journal:  Surg Infect (Larchmt)       Date:  2002       Impact factor: 2.150
View more
  17 in total

1.  Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against Pseudomonas aeruginosa in a Dynamic In Vitro Hollow-Fiber Infection Model.

Authors:  Aaron J Heffernan; Fekade B Sime; Derek S Sarovich; Michael Neely; Yarmarly Guerra-Valero; Saiyuri Naicker; Kyra Cottrell; Patrick Harris; Katherine T Andrews; David Ellwood; Steven C Wallis; Jeffrey Lipman; Keith Grimwood; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

2.  Treatment outcome of non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae infections: a multicenter study in Taiwan.

Authors:  Chin-Fang Su; Chien Chuang; Yi-Tsung Lin; Yu-Jiun Chan; Jung-Chung Lin; Po-Liang Lu; Ching-Tai Huang; Jann-Tay Wang; Yin-Ching Chuang; L Kristopher Siu; Chang-Phone Fung
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-12-14       Impact factor: 3.267

3.  Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.

Authors:  Ryan K Shields; Liang Chen; Shaoji Cheng; Kalyan D Chavda; Ellen G Press; Avin Snyder; Ruchi Pandey; Yohei Doi; Barry N Kreiswirth; M Hong Nguyen; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

4.  Characterization of Beta-Lactam Resistance Genes and Virulence Factors Associated with Multidrug-Resistant Klebsiella pneumoniae Isolated from Patients at Major Hospitals in Trinidad, West Indies.

Authors:  Aarti Pustam; Jayaraj Jayaraman; Adesh Ramsubhag
Journal:  Curr Microbiol       Date:  2022-08-03       Impact factor: 2.343

5.  Aminoglycoside-resistance gene signatures are predictive of aminoglycoside MICs for carbapenem-resistant Klebsiella pneumoniae.

Authors:  Yanqin Huang; Amisha P Rana; Eric Wenzler; Egon A Ozer; Fiorella Krapp; Jürgen B Bulitta; Alan R Hauser; Zackery P Bulman
Journal:  J Antimicrob Chemother       Date:  2022-02-02       Impact factor: 5.758

6.  Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.

Authors:  Ryan K Shields; Brian A Potoski; Ghady Haidar; Binghua Hao; Yohei Doi; Liang Chen; Ellen G Press; Barry N Kreiswirth; Cornelius J Clancy; M Hong Nguyen
Journal:  Clin Infect Dis       Date:  2016-09-13       Impact factor: 9.079

7.  Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance.

Authors:  Ryan K Shields; M Hong Nguyen; Binghua Hao; Ellen G Kline; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

8.  Optimizing aminoglycoside selection for KPC-producing Klebsiella pneumoniae with the aminoglycoside-modifying enzyme (AME) gene aac(6')-Ib.

Authors:  David A Butler; Amisha P Rana; Fiorella Krapp; Shitalben R Patel; Yanqin Huang; Egon A Ozer; Alan R Hauser; Zackery P Bulman
Journal:  J Antimicrob Chemother       Date:  2021-02-11       Impact factor: 5.790

9.  In Vitro Activity of Neomycin, Streptomycin, Paromomycin and Apramycin against Carbapenem-Resistant Enterobacteriaceae Clinical Strains.

Authors:  Ya Hu; Lu Liu; Xiaoxia Zhang; Yu Feng; Zhiyong Zong
Journal:  Front Microbiol       Date:  2017-11-17       Impact factor: 5.640

10.  Amikacin for the treatment of carbapenem-resistant Klebsiella pneumoniae infections: clinical efficacy and toxicity.

Authors:  Diógenes Rodrigues; Giulia Soska Baldissera; Douglas Mathos; Aline Sartori; Alexandre P Zavascki; Maria Helena Rigatto
Journal:  Braz J Microbiol       Date:  2021-06-30       Impact factor: 2.214
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.